Picture

AstraZeneca - ADDC Collaboration

The collaboration allows for ADDC members to have direct access to the AstraZeneca's library of compounds.

This collaboration between ADDC and AstraZeneca is aimed at at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application.
Click here for more information

Highlighted Partnerships

TB Drug Accelerator

  • The TB Drug Accelerator Programme aims to speed up the discovery and development of novel compounds against tuberculosis (TB).

SDDC

The DDU is now leading the SDDC. The Structure-guided Drug Discovery Coalition (SDDC) is an international research coalition led by the Structural Genomics Consortium, based at McGill University,...

Research Collaboration and license agreement

Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration...

Research Collaboration and license agreement

The Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in...

Research collaboration and license agreement

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for...

Number of Registered Partnerships

54

So Far
Therapeuitic Areas of Expertise
  • Choices
    Percentage
  • Oncology
     
    31.48%
  • Infectious Diseases
     
    18.52%
  • Neurological Disorders
     
    33.33%
  • Immunology
     
    22.22%
  • Metabolic Disorders
     
    20.37%
  • Cardiology
     
    12.96%
  • Pain
     
    7.41%
  • Other
     
    11.11%
  •  
Therapeutic Approaches
  • Choices
    Percentage
  • Small Molecules
     
    79.63%
  • Biologics
     
    37.04%
  • Biomarkers
     
    3.7%
  • Drug Delivery
     
    3.7%
  • Stem Cells
     
    3.7%
  • Vaccines
     
    1.85%
  • Antibodies
     
    9.26%
  • Other
     
    1.85%
  •